Support

Lorem ipsum dolor sit amet:

24h / 365days

We offer support for our customers

Mon - Fri 8:00am - 5:00pm (GMT +1)

Get in touch

Cybersteel Inc.
376-293 City Road, Suite 600
San Francisco, CA 94102

Have any questions?
+44 1234 567 890

Drop us a line
info@yourdomain.com

About us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.

Have any Questions? +49 33 767 - 791 10

Seramun News archive

June 2021

SERAMUN PARTICIPATES IN SARS-CoV-2 VACCINE STUDY

10. Jun 2021 /

Seramun Diagnosticas SeraSpot®Anti-SARS-CoV-2 IgG test was part of a vaccination study carried out by the Charité Berlin, Germany, from December 2020 to May 2021. The results of this study have now been published (https://www.medrxiv.org/content/10.1101/2021.05.19.21257334v2.full.pdf). It was shown that a heterologous ChAdOx / BNT vaccination with intervals of 10-12 weeks is well tolerated and just as immunogenic as a homologous BNT / BNT vaccination.

SARS-CoV-2-specific antibodies presence was examined with the SeraSpot®Anti-SARS-CoV-2 IgG - a microarray-based immunoassay - which comprises various SARS-CoV-2-specific antigens to distinguish between vaccine-induced antibody response and convalescent infection. Seramun is proud to contribute with its products to fighting against.

 

© Copyright 2001 - 2021   Seramun Diagnostica GmbH. All Rights Reserved.